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Abstract
With the emergence of multi-drug resistant bacteria the use of bacteriophages (phages) is
gaining renewed interest as promising anti-microbial agents. The aim of this study was to
isolate and characterize phages from human fecal samples. Three new coliphages,
ɸAPCEc01, ɸAPCEc02 and ɸAPCEc03, were isolated. Their phenotypic and genomic
characteristics, and lytic activity against biofilm, and in combination with ciprofloxacin, were
investigated. All three phages reduced the growth of E. coli strain DPC6051 at multiplicity of
infection (MOI) between 10−3 and 105. A cocktail of all three phages completely inhibited
the growth of E. coli. The phage cocktail also reduced biofilm formation and prevented the
emergence of phage-resistant mutants which occurred with single phage. When combined
with ciprofloxacin, phage alone or in cocktail inhibited the growth of E. coli and prevented
the emergence of resistant mutants. These three new phages are promising biocontrol
agents for E. coli infections.
Introduction
Several members of the Escherichia coli species have emerged as important human pathogens.
For example, E. coliO157:H7 can be the cause of acute diarrhea, hemorrhagic colitis and hemo-
lytic uremic syndrome [1]. Shiga toxin-producing E. coli (STEC) and enteropathogenic E. coli
(EPEC) are of particular concern, as they cause infections which can be fatal in sensitive popu-
lations [2, 3]. The emergence of multi-drug resistant bacterial strains is increasing [4] and alter-
native treatments to antibiotics are urgently required.
Bacteriophages (phages), viruses of bacteria, have been exploited for their potential as anti-
bacterial agents since their discovery over 100 years ago [5, 6]. Some phage preparations, such
as ListShield™ and LISTEX™ P100, are now approved for the control of pathogenic bacteria in
food [7, 8]. The veterinary use of phage as feed additives to prevent E. coli infection in animals
is currently being examined. For example, pigs infected with enterotoxigenic E. coli (ETEC)
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showed more resistance to diarrhea due to ETEC infection when treated with phages than
non-phage treated animals [9]. While phages have been extensively used in some countries of
Eastern Europe for clinical purposes, there is still no approved phage treatment in the Western
world [8]. Recently it has been shown that phages efficiently reduced the number of enteroag-
gregative E. coli cells in the gut of mice [10]. Some studies have established the safety of T4
phage cocktails applied orally in humans, establishing that they do not cause adverse effects on
host health and that they do not affect the commensal microbiota [11, 12]. By discovering new
phages effective against pathogenic bacteria, it is possible to develop alternative treatment
methods either for food safety, veterinary or clinical use.
The aim of this study was to isolate and characterize new bacteriophages from the human
gut against E. coli, and to investigate their antibacterial properties alone and in cocktail.
Material and Methods
Strains, phage isolation from faecal samples, and host range
determination
The strains used in this study have previously been characterized and are kept in the collections
of Moorepark Food Research Centre (Ireland) and University College Cork (Ireland) (Table 1).
Thirty frozen faecal samples, 20 from community patients and 10 from patients in long-term
care facilities, from the ELDERMET project [13], were used to isolate phages. Ethical approval
was provided by the Cork Clinical Research Ethics Committee. The samples used in this study
have been described in a previous publication [14]. Briefly, 0.5 g of sample were suspended in
10 ml sterile saline magnesium buffer (100 mMNaCl, 8 mMMgSO4, 50 mM Tris [pH 7.5],
and 0.002% [wt/vol] gelatin), mixed by vortexing for 10 min and centrifuged twice at 2500×g
for 10 min at 4°C. The supernatant was then filtered sterile with 0.45 μm syringe filters. 100 μl
of filtrate were mixed with 100 μl of an overnight culture of the target E. coli strain (DPC6009,
DPC6050, DPC6051, DPC6054, DPC6055, E2348/68) (Table 1), before mixing with 3 ml of LB
agar (0.5% agar, Oxoid, Basingstoke, United kingdom) containing 10 mMMgSO4, and poured
on top of a LB agar plate. The plates were incubated at 37°C until formation of plaques. Phages
ɸAPCEc01, ɸAPCEc02, and ɸAPCEc03 all got strain DPC6051 as primary host. Host range
determination was performed using spot tests using a methodology previously described [15].
As strain DPC6051 was the host used to isolate the three phages, it was used in all the assays
presented in this study.
One-step growth curve
One-step growth experiments were performed in triplicate to assess the burst size, and latency
and rise phases of phages ɸAPCEc01, ɸAPCEc02, and ɸAPCEc03 using a method previously
described [25] with the following modifications. Incubations were performed in LB broth sup-
plemented with 10 mMMgSO4, at 37°C. A multiplicity of infection (MOI) of about 0.001 was
used. The burst size was calculated by using the following formula, where “titer after burst” is
the phage titer after the initial burst and “phage added” is the phage titer added before adsorp-
tion (7.8 × 104 pfu/ml, 1.6 × 104 pfu/ml and 4.2 × 104 pfu/ml for phages ɸAPCEc01,
ɸAPCEc02, and ɸAPCEc03, respectively): burst size = (titer after burst—titer at T0)/(phage
added—titer at T0) [25].
Bacterial challenge tests and phage activity against E. coli biofilms
Bacterial challenge tests and biofilm assays were performed in 96-well plates, in triplicate. For
both tests, each condition was tested in 8 wells of the plate, containing 100 μl of diluted culture
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and 100 μl of diluted phage lysate. Phage lysate dilutions were performed in phage buffer (20
mM Tris-HCl [pH 7.2], 10 mMNaCl, 20 mMMgSO4). When using a combination of the three
phages, each single phage was added in equal proportions to create the cocktail. The positive
control wells contained only the bacterial culture and 100 μl of phage buffer.
For the bacterial challenge tests, the microplate was filled with an overnight culture of E. coli
DPC6051 strain diluted in 2× LB broth containing 20 mMMgSO4 to obtain cell numbers of
104 cfu/ml. This is of particular interest in the context of food decontamination where patho-
genic bacteria are present at low concentrations. The tested conditions were phage MOI’s val-
ues ranging from 10−3 to 104. The plate was incubated at 37°C for 24 h. The optical density
(OD600nm) was measured in each well at the end of incubation.
For the biofilm assays, 20 ml of LB broth were inoculated with 200 μl of an overnight culture
of strain DPC6051, and were used to fill the microplate, before being incubated at 37°C for 24
h to allow the bacterial cells to adhere to the wells. After removing the liquid culture without
disturbing the cells attached to the wells as for the rest of the procedure, the wells were washed
with PBS, and filled with 100 μl of 2× LB broth containing 20 mMMgSO4 and 100 μl of lysate
dilutions. The plates were incubated at 37°C up to 48 h. The tested conditions were phage
Table 1. Strains used in this study and host range of phages ɸAPCEc01, ɸAPCEc02 and ɸAPCEc03.
Phage host range
Strain Strain designation Description Reference ɸAPCEc01 ɸAPCEc02 ɸAPCEc03
E. coli 042 EAEC O44:H18, patient with diarrhea [16] - - -
E. coli 2348/69 EPEC O127:H6, outbreak of infantile
diarrhea
[17] - - -
E. coli O157:H7 Sakai Δshx (RIMD
0509952)
EHEC O157:H7, Sakai outbreak [18] - - +
E. coli H10407 ETEC O78:H11:K80, adult with cholera-
like symptoms
[19] - - +
E. coli HM605 Colonic mucosal isolate from a Crohn’s
disease patient
[20] - - -
E. coli MG1655 - + +
E. coli A0 34/86 O83:K24:H31, commensal porcine isolate [21] - - -
E. coli Nissle - - +
E. coli UTI89 Patient with cystitis [22] - - -
E. coli CFT073 Pyelonephritis isolate [23] - - -
E. coli DPC6009 NA + + +
E. coli DPC6050 NA + + +
E. coli DPC6051 NA + + +
E. coli O157:H7 DPC6054 Non toxigenic - + +
E. coli O157:H7 DPC6055 Non toxigenic - - +
E. coli EPEC E2348/68 NA - - -
Shigella sonnei Patient with shigellosis + - -
Salmonella
Typhimurium
DPC6046 Pig carcass swab [24] - - -
Salmonella
Typhimurium
DPC6452 Faecal sample - - -
+ Presence of a clear lytic zone
- Absence of lytic zone
NA: Not available
doi:10.1371/journal.pone.0156773.t001
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concentrations ranging from 102 to 109 phages per well. A colorimetric assay with XTT con-
taining menadione was performed as previously described [26, 27], to assess the metabolic
activity of the bacterial cells in the biofilm after phage treatment. Briefly, the biofilms were
gently washed with phosphate buffered saline, then 100 μL of a solution containing 500 mg
XTT/L (2,3-bis[2-methyloxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide) (Sigma)
and 50 μMmenadione (Sigma) was added to each well. After a 2 h-incubation in the dark, the
absorbance was measured at 492 nm using a microtiter plate reader (Molecular Devices Spec-
tramax M3, Sunnyvale CA, USA). A Student’s t-test was performed to assess the significance of
the phage action for both tests (p<0.05).
Phage and antibiotic combination against E. coli
Combinations of phage (MOI of 1) and 4 μg/ml of ciprofloxacin HCl (MIC of 5 μg/ml) (Santa-
Cruz Biotechnology, Dallas, USA) were tested in triplicate against a growing culture of strain
DPC6051 (8.1 ± 0.04 log cfu/ml), in 5 ml LB supplemented with 10 mMMgSO4, and incubated
at 37°C for 24 h. Ciprofloxacin is an antibiotic of the fluoroquinolone class, that inhibits bacte-
rial replication by acting on DNA gyrases.
A miniaturized enumeration method previously described [28] was performed to evaluate
the frequency of antibiotic-resistant mutants after phage-antibiotic treatment. The threshold of
detection was 20 cfu/ml.
Transmission electron microscopic (TEM) analysis
Phage lysates were purified on a cesium chloride gradient by ultracentrifugation [25], and
100 μl were dialyzed against phage buffer for 20 min on 0.025 μmVSWP membrane filters
(Merck Millipore). Negative staining of phages and transmission electron microscopic analysis
were performed as previously described [29].
DNA extraction and genome sequencing
DNA was extracted from the cesium chloride purified fractions as previously described [25].
DNA samples were sent to GATC (Germany) for whole phage genome sequencing using an
Illumina HiSeq 2500 sequencer with 2x100 bp read length. The reads generated by the Illumina
instrument were assembled at GATC.
In silico analysis of the genomes
Protein-encoding open reading frames (ORFs) were predicted using Glimmer [30]. Initial
functional annotation of the ORFs and percentage amino acid identities were determined
using BLASTP[31] and RAST server [32]. Transfer RNAs (tRNAs) were screened in the
genomes using ARAGORN [33].
The BRIG software [34] was used for genome comparison of phage genomes which gave the
best hit scores using BLASTP. Consequently, ɸAPCEc01 genome was compared to E. coli
phages T4, vB_EcoM_JS09, RB27, vB_EcoM-VR7, Av-05, HX01, vB_EcoM_PhAPEC2, and
RB69 (GenBank numbers NC_000866, NC_024124, NC_025448, NC_014792, KM190144,
NC_018855, NC_024794, and NC_004928, respectively), and to Shigella phage Shf125875
(GenBank KM407600). ɸAPCEc02 genome was compared to E. coli phages rv5, 2 JES-2013,
vB_EcoM_FFH2, and vB_EcoM-FV3 (GenBank numbers NC_011041, NC_022323,
NC_024134, and NC_019517, respectively). ɸAPCEc03 genome was compared to E. coli
phages T5, bV_EcoS_AKFV33, DT57C, DT571/2, and vB_EcoS_FFH1 (GenBank numbers
NC_005859, NC_017969, KM979354, KM979355, and KJ190157, respectively), to Salmonella
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phages SPC35, Shivani, and Stitch (GenBank numbers HQ406778, KP143763, and KM236244,
respectively), and to Yersinia phage phiR201 (GenBank HE956708).
Accession numbers
The complete genome sequences of ɸAPCEc01, ɸAPCEc02 and ɸAPCEc03 have been depos-
ited in GenBank under accession numbers KR422352, KR698074 and KR422353, respectively.
Results and Discussion
Phage morphology
The human gut is a natural reservoir of numerous phages with promising antibacterial activi-
ties [35]. Three new E. coli phages, ɸAPCEc01, ɸAPCEc02, and ɸAPCEc03, were isolated from
three different human faecal samples of elderly patients, all in long-term care with no known
health disorder [36]. The samples from which the phages were isolated did not display remark-
able bacterial traits compared to the other samples. The percentages of E. coli/Shigella were
2.08%, 0.07% and 0.24% in the samples where ɸAPCEc01, ɸAPCEc02, and ɸAPCEc03 were
isolated respectively [36].
TEM analysis showed that phages ɸAPCEc01 and ɸAPCEc02 have contractile tails charac-
teristic of theMyoviridae family (Fig 1a and 1b). Phage ɸAPCEc01 has a prolate head, and six
thin bent tail fibres and short tail spikes attached below the baseplates (Fig 1a). The morpho-
logical characteristics and dimensions of phage ɸAPCEc01 (Table 2) are in accordance with T4
Fig 1. Transmission electronmicrographs of E. coli phages ɸAPCEc01 (a), ɸAPCEc02 (b), and
ɸAPCEc03 (c). The thin arrows in micrograph c indicate the 3 flexible fibres attached to the distal end of the
phage tail. The terminal baseplate spike in c is illustrated by the thick arrow.
doi:10.1371/journal.pone.0156773.g001
Table 2. Dimensions of the three E. coli phages isolated in this study.
ɸAPCEc01 ɸAPCEc02 ɸAPCEc03
Family Myoviridae Myoviridae Siphoviridae
Head morphology Prolate Isometric Isometric
Head dimensionsa 118.5 ± 3.3 [n = 12]b x 84.8 ± 5.1 [n = 13] Ø 82.6 ± 4.6 [n = 8] Ø 78.8 ± 3.7 [n = 11]
Tail lengtha 112.2 ± 1.8 [n = 13] 119.0 ± 3.7 [n = 7] 188.8 ± 5.5 [n = 10]
Tail widtha 20.9 ± 1.2 [n = 13] 20.3 ± 1.3 [n = 7] 12.0 ± 1.5 [n = 9]
Tail ﬁbre lengtha 152.0 ± 4.8 [n = 11] 46.0 ± 3.4 [n = 8] 53.0 ± 2.1 [n = 9]
Tail spike lengtha 15.5 ± 2.1 [n = 15] 43.6 ± 5.6 [n = 6]
a Dimensions are expressed in nm
b[number of measurements]
doi:10.1371/journal.pone.0156773.t002
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phage morphology [37]. Phage ɸAPCEc02 has an isodiametric head, and six short tail fibres
attached to the baseplate (Fig 1b). Its morphological characteristics and dimensions (Table 2)
are consistent with that of rV5-like phages [38, 39]. Phage ɸAPCEc03 has an isometric head, a
flexible non-contractile tail, a characteristic distal tail spike, and three flexible bent fibres with
distal globular structures (Fig 1c). Phage ɸAPCEc03 morphology and dimensions (Table 2) are
characteristic of T5 phage from the Siphoviridae family [40].
Host range
Phage ɸAPCEc03 had the broadest host range and targeted 9 out of the 16 E. coli strains tested,
including an E. coli O157:H7 strain, an enterohaemorrhagic E. coli (EHEC) strain and an
ETEC strain (Table 1). This broad host range makes phage ɸAPCEc03 an interesting candidate
as a biocontrol agent, for example along the farm-to-fork chain, where E. coli is one of the most
frequently encountered food pathogens [41], or for clinical purposes for treating E. coli infec-
tions [42, 43]. Phage ɸAPCEc02 targeted five E. coli strains, including an E. coli O157:H7 strain
(Table 1). Interestingly, ɸAPCEc01 targeted three E. coli strains and a Shigella sonnei strain
(Table 1). S. sonnei is responsible for diarrheal disease in industrialized countries and more
recently in developing countries [44]. A siphophage infecting these two species has also been
reported [45]. The fact the ɸAPCEc01 can target two bacterial genera is an asset of this phage
for potential use as antimicrobial agent. In all cases, a higher number of appropriate strains
should be tested in order to assess the full range of action of the three phages before considering
their future application as antimicrobial agents. It is also necessary to use cocktails of multiple
phages due to the great diversity of E. coli strains and thus to overcome the narrow host range
of some phages. Besides, other methods for testing phage host range, like efficiency of plating
on secondary hosts, could also be performed to avoid false positive in the case of lysis from
without phenomenon [46, 47].
Phage population dynamics
One-step growth experiments were performed to assess the population kinetics of ɸAPCEc01,
ɸAPCEc02 and ɸAPCEc03 in the presence of E. coli strain DPC6051 (Fig 2). All phages had a
latent phase of 10 min. ɸAPCEc01 had a rise phase of 60 min (Fig 2a), and had a burst size of
90.3 ± 1.4 phage particles. These results are characteristic ofMyoviridae phages, which display
latent periods ranging from 20 to 120 min and burst sizes of up to 100 phage particles [48].
The lytic cycle of ɸAPCEc02 was characterized by a rise phase of 40 min (Fig 2b). Its calculated
burst size was rather small with only 30.8 ± 1.9 phage particles. APCEc03 had population
dynamics characteristic of phage EP23, another E. coli Siphoviridae phage [45], with a rise
phase of 40 min, and a burst size of 47.4 ± 11.3 phage particles (Fig 2c).
Key feature of the genomes
The length of the assembled genomes of ɸAPCEc01, ɸAPCEc02 and ɸAPCEc03 was 168,771
bp, 135,400 bp and 103,737 bp, respectively. The GC content of ɸAPCEc01, ɸAPCEc02 and
ɸAPCEc03 was 37.7%, 43.6%, and 38.9%, respectively (Table 3). The GC content of these three
phages is lower than the GC content of E. coli which is around 50% [17], suggesting that some
elements of the phage genomes may have been acquired from other phages infecting hosts with
a lower GC content or could have evolved from an ancestor that infected a host with a lower
GC content.
ɸAPCEc01 genome had 94.7% (272 ORFs) coding regions whereas ɸAPCEc02 and
ɸAPCEc03 had 89.1% (218 ORFs) and 85.9% (151 ORFs) coding regions, respectively
(Table 3). For all phages, gene annotation did not identify known toxins or toxin-related
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pFAM domains. In addition, no genomic markers indicating a temperate lifestyle were found
(S1, S2 and S3 Tables). These latter genetic characteristics make these phages suitable candi-
dates for phage therapy purposes as the absence of lysogenic traits and virulence factors are
mandatory for phages being considered as biocontrol agents [49].
Table 3. Genome features of phages ɸAPCEc01, ɸAPCEc02 and ɸAPCEc03.
ɸAPCEc01 ɸAPCEc02 ɸAPCEc03
Length (bp) 168,771 135,400 103,737
No. of ORFs 272 219 151
No. of tRNAs 2 5 8
GC content (%) 37.7 43.6 38.9
A (%) 31.8 29 31.2
T (%) 30.5 27.5 29.9
C (%) 18.1 21.3 19
G (%) 19.5 22.3 19.9
% genome coding 94.7 89.1 85.9
doi:10.1371/journal.pone.0156773.t003
Fig 2. One-step growth curves of phages ɸAPCEc01 (a), ɸAPCEc02 (b), and ɸAPCEc03 (c) with E. coli
strain DPC6051 in LB broth at 37°C.
doi:10.1371/journal.pone.0156773.g002
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ɸAPCEc01 genome
Phage ɸAPCEc01 genome is closely related at the nucleotide level to Shigella phage shf125875
(Fig 3a). This is in accordance with the fact that ɸAPCEc01 targets both E. coli and Shigella
strains (Table 1). ɸAPCEc01 genome also shares at least 90% identity at the nucleotide level
with four other T4-like E. coli phages, two of which (i.e., phages HX01 and vB_EcoM_PhA-
PEC2) have been used against avian pathogenic E. coli strains [50, 51] (Fig 3a). Of the 272
ORFs, 117 (43%) could be assigned a putative function. The conserved ORFs such as genes
coding terminase, phage head and tail structural proteins, polymerase, and lysozyme show
high identity hits with these phages (S1 Table). The T4-like phages have already been described
as safe in numerous phage therapy applications [52], with no impact on commensal micro-
biota, while helping in the reduction of infection with E. coli.[53] A phage cocktail of at least
ten T4 phages was even proposed to cover the five main E. coli pathotypes isolated from diar-
rhea patients [53]. This enhances the potential of phage ɸAPCEc01 for phage therapy purposes
and the need to combine it with other phages in a phage cocktail.
ɸAPCEc02 genome
The ɸAPCEc02 genome is closely related at the nucleotide level to four other rv5-like E. coli
phages [38] (Fig 3b). The ORFs of ɸAPCEc02 share between 77 and 100% identity at the
amino acid level with homologous ORFs of these four phages, with the exception of ORFs 65,
66, 208 and 209 (S2 Table). Of the identified 219 ORFs, only 50 (23%) could be assigned a puta-
tive function. This small number of ORFs with assigned functions emphasizes the need for the
characterization of new phage genomes, which can only be achieved by the isolation and com-
parative analysis of new phages such as those in this study [54].
ɸAPCEc03 genome
Of the 151 identified ORFs, 56 ORFS of ɸAPCEc03 (37%) could be assigned a putative func-
tion. With the exception of ORF38 coding for a homing endonuclease, all 56 ORFs of know
functions share at least 87% identity at the amino acid level with homologues in twelve other
phages, including four E. coli phages, three Salmonella phages and a Yersinia phage (S3 Table,
Fig 3c). This is not unexpected, as the T5-like phage SPC35 was also found to target both S.
enterica serovar Typhimurium and E. coli [55]. Despite these genetic similarities to other phage
species genomes, ɸAPCEc03 did not lyse the Salmonella strains tested in this study, hence it
would require to be tested against a broader range of strains to draw any conclusions as to its
efficiency against species other than E. coli.
Effect of phages on E. coli growing culture and biofilms
As the genome features of the three phages did not exhibit any lysogenic or virulence factors,
their potential as biocontrol agents against E. coli was evaluated. E. coli strain DPC6051 was sen-
sitive to the three phages, and consequently was chosen as model strain in the subsequent part
of the study. The effect of ɸAPCEc01, ɸAPCEc02 and ɸAPCEc03, alone or in cocktail, on the
growth of strain DPC6051 was tested at different MOIs after 24 h of contact between the strain
and the phages (Fig 4). The three phages significantly inhibited (p<0.001) or reduced (p<0.05)
the growth of the E. coli strain at all tested MOIs (Fig 4a, 4b and 4c). This was especially true at
MOI’s values greater than 1, for which the OD600nm value of the culture was close to the
OD600nm value of the uninoculated broth. In the case of phage ɸAPCEc03, OD values seemed to
increase with increasing MOIs (Fig 4c) for MOI’s values between 0.01 and 0.1. This increase in
OD was however not significant (p>0.05) for the three values of MOI tested. A three-phage
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Fig 3. BLAST Ring Image Generator representation of phage ɸAPCEc01 (a), ɸAPCEc02 (b), and
ɸAPCEc03 (c) genomes. The innermost rings show the GC content (black) and GC skew (purple: GC skew
[-]; green: GC skew[+]). For each comparison using BRIG, the longest phage genome was used as a
reference, and its name is indicated in the middle of the rings. The circles represent the genomes of the
phages compared to this reference including the phages described in this study.
doi:10.1371/journal.pone.0156773.g003
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cocktail also inhibited the growth of the E. coli strain at all the tested MOIs (Fig 4d). These
results prove the efficiency of the phages alone or in a cocktail to reduce the growth of E. coli.
E. coli is able to form and survive in biofilms, which control and prevention are a serious
challenges in medicine [56]. In the current study, the action of phages alone and in cocktail
against a biofilm formed by E.coli strain DPC6051 was assessed in a model system after 24 h
and 48 h of contact with the phage (Fig 5). The metabolic activity of the cells forming the bio-
film was measured using a tetrazolium salt (XTT) assay, XTT being only reduced by metaboli-
cally active cells to a coloured water-soluble formazan derivative quantified by colorimetry
[26]. The activity of the biofilm was drastically reduced by at least 4-fold after 24 h of contact
with phage ɸAPCEc01 at doses higher than 107 plaque forming units (pfu)/well (Fig 5a). At
lower doses, the biofilm activity was not reduced. After 48 h of contact with ɸAPCEc01, the
metabolic activity of the biofilm significantly increased at all phage doses. This indicates the
possible emergence of bacteriophage-insensitive mutants (BIMs) in the biofilm. The appear-
ance of E. coli BIMs at a low frequency has been described in another bacterial challenge trial
with single phages and phage cocktails [57]. The same tendencies at 24 h and 48 h were
observed when the biofilm was in contact with ɸAPCEc02 (Fig 5b). The biofilm metabolic
Fig 4. Bacterial challenge test. The optical density (OD600nm) was measured after 24 h of contact between
E. coli strain DPC6051 and phage ɸAPCEc01 (a), phage ɸAPCEc02 (b), phage ɸAPCEc03 (c), and a
cocktail of the three phages (d). *** p<0.001, * p<0.05.
doi:10.1371/journal.pone.0156773.g004
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activity significantly decreased after 24 h of contact with ɸAPCEc03 (p< 0.001), and remained
the same or even kept decreasing after another 48 h (Fig 5c). The phage cocktail at doses higher
than 103 pfu/well significantly reduced the biofilm metabolic activity by at least 1.2-fold
(p<0.001) and almost eliminated all activity at 109 pfu/well (Fig 5d). Another 48 h-incubation
step in the presence of the phage cocktail again resulted in the maintenance or in a significant
decrease in the biofilm metabolic activity (p<0.05). Based on these results, the phage cocktail
represents a suitable biocontrol agent for the reduction and control of E. coli biofilms. It pre-
vented the appearance of BIMs which are likely to occur with single phage [57], bearing in
mind that phage activity also depends upon multiple factors such as the complex biofilm com-
position, the accessibility of the target bacteria within the biofilm and the environmental condi-
tions [58].
Fig 5. Effect of single phages ɸAPCEc01 (a), ɸAPCEc02 (b), ɸAPCEc03 (c), and a three-phage cocktail
(d) on a 24 h-biofilm formed by E. coli strain DPC6051, after 24 h (■) and 48 h (■) of contact between
phage and bioﬁlm. Bioﬁlm activity was assessed by OD492nm measures after treatment with XTT
supplemented with menadione. ***p<0.001; **p<0.01; *p<0.05.
doi:10.1371/journal.pone.0156773.g005
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Combination of phage and antibiotic
The combination of antibiotics and phage has been shown to efficiently reduce the growth of
E. coli, and to greatly limit the emergence of antibiotic and phage resistant cells [59]. We inves-
tigated these aspects with the new coliphages when combined with ciprofloxacin. A growing
culture of E. coli strain DPC6051 was incubated for 24 h at 37°C in the presence of a combina-
tion of ciprofloxacin (minimum inhibitory concentration (MIC) of 5 μg/ml) and phages
ɸAPCEc01, ɸAPCEc02 and ɸAPCEc03, alone or in cocktail (MOI of 1) (Fig 6). The combina-
tion of antibiotic and phage decreased the number of live cells of 3.9 and 1.9 log colony forming
units (cfu)/ml compared to phage ɸAPCEc01 and ɸAPCEc02 used alone, respectively, and of
4.3 and 1.1 log cfu/ml compared to antibiotic used alone. These results are in accordance with
previous observations of phage-antibiotic synergy limiting the appearance of resistant mutants
[60]. In the case of ɸAPCEc03, live cells could not be detected with the combination of antibi-
otic and phage, indicating the complete inhibition of emergence of antibiotic and phage resis-
tant bacterial cells. These observations are congruent with previous results showing that
antibiotics, such as ciprofloxacin, can be combined with phages to stimulate increased phage
production and/or activity and thus improve the efficacy of bacterial killing [61]. Surprisingly,
no significant synergetic effect of the antibiotic and the phage cocktail was observed. Nonethe-
less, the reduction in the number of live cells was of almost 6 log cfu/ml with the phage cocktail
compared to the control. The phage cocktail also reduced the number of live cells of almost 4
log cfu/ml when compared to the use of ciprofloxacin alone. These three new phages are there-
fore suitable for usage in combination with antibiotics as they noticeably reduced the emer-
gence of resistant cells when combined with ciprofloxacin. More antibiotics would need to be
tested to evaluate the synergy range of the new phages with other antibiotics.
In conclusion, three new E. coli phages were isolated from human faeces samples in this
study. These novel phages show promise as antimicrobial agents especially when used in a
cocktail to prevent E. coli growth and biofilm formation. They can also be considered as com-
plementary treatments to antibiotics by helping to prevent the appearance of resistant mutants.
This study underlines the importance of mining the human gut for isolating and exploiting
new antimicrobial agents such as phages [35].
Fig 6. Effect of a combination of ciprofloxacin HCl and phages ɸAPCEc01, ɸAPCEc02, and
ɸAPCEc03, alone or in cocktail, on the growth of E. coli strain DPC6051. Each condition was tested in
triplicate. Bacterial counts were performed after 24 h of incubation, with a detection threshold of 20 cfu/ml.
*** p<0.001, ** p<0.01, * p<0.05.
doi:10.1371/journal.pone.0156773.g006
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